Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04521621
Title	A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013)
Recruitment	Terminated
Gender	both
Phase	Phase Ib/II
Variant Requirements	No
Sponsors	Merck Sharp & Dohme Corp.
Indications	hypopharynx cancer laryngeal squamous cell carcinoma Advanced Solid Tumor gastric adenocarcinoma hepatocellular carcinoma breast cancer stomach carcinoma oropharynx cancer gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma triple-receptor negative breast cancer skin squamous cell carcinoma oral squamous cell carcinoma
Therapies	Coxsackievirus A21 + Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA \| POL \| NOR \| ITA \| ISR \| HUN \| FRA \| ESP \| DEU \| CAN